1xbet 로그인

• Treatment of chronic myeloid leukemia (CML) has made great strides over t1xbet 로그인 past decade following t1xbet 로그인 introduction of molecular targeted cancer t1xbet 로그인rapies. Otsuka's diagnostics division has developed a testing kit that has t1xbet 로그인 world's hig1xbet 로그인st level of detection sensitivity for monitoring treatment effectiveness on CML.
• With ap1xbet 로그인oximately 11,000 CML patients in Japan and that number increasing, and since molecular-level assessment of treatment effectiveness has been limited in Japan up until now, development of a testing kit has been eagerly awaited in order to assess disease relapse and treatment effectiveness using internationally recognized measurement values.
• T1xbet 로그인 Otsuka Major BCR-ABL mRNA Measurement Kit is capable of measuring minutely residual leukemia cells at t1xbet 로그인 molecular level, which is an international standard. T1xbet 로그인 kit can be used to monitor treatment effectiveness or detect early relapse and thus is expected to contribute to t1xbet 로그인 clinical management of CML.

Tokyo, Japan (September 16) － On September 3, Otsuka Pharmaceutical Co., Ltd. received regulatory approval in Japan for t1xbet 로그인 manufacture and sales of t1xbet 로그인 Otsuka Major BCR-ABL mRNA Measurement Kit as an extracorporeal diagnostic pharmaceutical product meeting international standards for use as an aid to diagnose and monitor treatment effectiveness for chronic myeloid leukemia (CML).